HK inno.N Corporation (195940.KQ)
- Previous Close
40,900.00 - Open
40,900.00 - Bid 41,400.00 x --
- Ask 41,450.00 x --
- Day's Range
40,750.00 - 41,600.00 - 52 Week Range
31,650.00 - 52,000.00 - Volume
68,981 - Avg. Volume
212,631 - Market Cap (intraday)
1.173T - Beta (5Y Monthly) 0.69
- PE Ratio (TTM)
-- - EPS (TTM)
-- - Earnings Date --
- Forward Dividend & Yield 350.00 (0.86%)
- Ex-Dividend Date Mar 28, 2025
- 1y Target Est
59,916.67
HK inno.N Corporation engages in the pharmaceutical business in South Korea. The company offers prescription drugs for the treatment of gram-positive and gram-negative organisms, enterococcus faecium infections, vancomycin-resistant, acute bacterial sinusitis, bronchitis, neumonia, antibiotics, and infections caused by microorganism; anemia and hemodialysis; diabetes; hypertension, primary hypercholesterinemia, homozygous familial hypercholesterolemia, and hypertension with dyslipidemia; GERD, EE, NERD, GU and H.Pylori; pleural mesothelioma, non-small cell lung cancer, and mesothelioma, and colorectal cancer; and nutrition and intravenous nutrition. It also provides health and beverage products, such as hangover relief, ready to drink, health supplements and health functional foods, as well as active pharmaceutical ingredients. In addition, the company offers beauty products under the bewants, ScalpMed, and KLEDERMA RX brands. It also exports its products to Japan, Southeast Asia, Latin America, Europe, and the Middle East countries. HK inno.N Corporation was founded in 1984 and is headquartered in Cheongju-si, South Korea.
www.inno-n.com1,694
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: 195940.KQ
View MorePerformance Overview: 195940.KQ
Trailing total returns as of 5/15/2025, which may include dividends or other distributions. Benchmark is KOSPI Composite Index (^KS11) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 195940.KQ
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 195940.KQ
View MoreValuation Measures
Market Cap
1.16T
Enterprise Value
1.52T
Trailing P/E
18.81
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.29
Price/Book (mrq)
0.93
Enterprise Value/Revenue
1.69
Enterprise Value/EBITDA
12.01
Financial Highlights
Profitability and Income Statement
Profit Margin
5.34%
Return on Assets (ttm)
2.11%
Return on Equity (ttm)
3.90%
Revenue (ttm)
839.63B
Net Income Avi to Common (ttm)
41.49B
Diluted EPS (ttm)
--
Balance Sheet and Cash Flow
Total Cash (mrq)
136.45B
Total Debt/Equity (mrq)
39.75%
Levered Free Cash Flow (ttm)
-6.63B